Article Text


627 Initial Experiences with Propranolol Treatment of Infantile Hemangiomas: Report of Eight Cases
  1. K Lajmi,
  2. A Hellara,
  3. S Hammami,
  4. S Haddad,
  5. C Ben Meriem,
  6. MN Gueddiche
  1. Fattouma Bourguiba Hospital, Monastir, Tunisia


Background The infantile hemangioma (IH) is the most common benign vascular tumor in children. The most cases do not require therapeutic intervention. However, 10% of these cases require a treatment because of a life-threat, a functional trouble, a local complication or esthetic risk. We study the efficiency of Propranolol in the control of infantile hemangioma.

Methods Eight infants presented with 8 infantile hemangiomas treated by oral propranolol at a dose of 2 mg/kg body weight per day. Treatment outcomes were clinically evaluated.

Results The treatment was initiated during infancy in all cases (mean, 12.7 months). five patients were treated with 2 mg/kg per day, and three with 3 mg/kg per day Patients were monitored at initiation of treatment The first noticeable effects on propranolol treatment were the changes in color and softening of hemangiomas, followed by regression of their sizes and deep. Response to treatment was favorable; five showed total regression and in three cases a partial regression The average treatment duration in the remaining patients was 6.1 months. no adverse events were reported.

Conclusion Propranolol is an efficacious therapy for infantile hemangiomas. Risks and complications appear moderate. Prospective controlled trails are necessary to observe the effects on a long-term basis.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.